|
04.01.2013 23:13:00
|
Endo Health Solutions Inc. -- Moody's: Endo litigation and Opana generics are credit negative
New York, January 04, 2013 -- Moody's Investors Service commented that recent developments affecting Endo Health Solutions Inc. ("Endo") related to a new litigation charge and pending generic competition for Opana are credit negative. However, there is currently no change to Endo's Ba2 Corporate Family Rating or the stable rating outlook.
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.